Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0036341
Disease: Schizophrenia
Schizophrenia
0.340 Biomarker disease BEFREE Previous work has demonstrated that the STriatal-Enriched protein tyrosine Phosphatase 61 kDa (STEP<sub>61</sub>) is elevated in human SZ postmortem cortical samples and after administration of psychotomimetics to cultures or mice. 28466270 2018
CUI: C0036341
Disease: Schizophrenia
Schizophrenia
0.340 AlteredExpression disease BEFREE In frontal cortex we observed: 1) reduced expression of 120 kDa form of APP in subjects with schizophrenia and bipolar disorder; 2) reduced expression of 61 kDa and 33k Da forms of STEP in subjects with schizophrenia; 3) reduced expression of 88 kDa form of APP in subjects with bipolar disorder; and 3) trends for reduced expression of 88 kDa form of APP and homer 1 in subjects with schizophrenia and bipolar disorder, respectively. 25956630 2015
CUI: C0036341
Disease: Schizophrenia
Schizophrenia
0.340 Biomarker disease BEFREE Taken together, our findings suggest that STEP(61) accumulation may contribute to the pathophysiology of SZ. 22781170 2012
CUI: C0036341
Disease: Schizophrenia
Schizophrenia
0.340 Biomarker disease PSYGENET Taken together, our findings suggest that STEP(61) accumulation may contribute to the pathophysiology of SZ. 22781170 2012
CUI: C0036341
Disease: Schizophrenia
Schizophrenia
0.340 Biomarker disease BEFREE In this study, we examined the association of the protein tyrosine phosphatase non-receptor 5 (PTPN5) gene, which encodes for STEP, with both schizophrenia and cognitive functioning in the Israeli Jewish population. 22555153 2012
CUI: C0036341
Disease: Schizophrenia
Schizophrenia
0.340 Biomarker disease PSYGENET In this study, we examined the association of the protein tyrosine phosphatase non-receptor 5 (PTPN5) gene, which encodes for STEP, with both schizophrenia and cognitive functioning in the Israeli Jewish population. 22555153 2012
CUI: C0027746
Disease: Nerve Degeneration
Nerve Degeneration
0.300 Biomarker phenotype CTD_human Status epilepticus-induced somatostatinergic hilar interneuron degeneration is regulated by striatal enriched protein tyrosine phosphatase. 17360923 2007
CUI: C0007787
Disease: Transient Ischemic Attack
Transient Ischemic Attack
0.200 Therapeutic disease RGD Neuroprotective role of a brain-enriched tyrosine phosphatase, STEP, in focal cerebral ischemia. 24198371 2013
CUI: C0007787
Disease: Transient Ischemic Attack
Transient Ischemic Attack
0.200 Biomarker disease RGD Neuroprotective role of a brain-enriched tyrosine phosphatase, STEP, in focal cerebral ischemia. 24198371 2013
CUI: C0752308
Disease: Hypoxia-Ischemia, Brain
Hypoxia-Ischemia, Brain
0.200 Biomarker disease RGD Hypoxia-ischemia in perinatal rat brain induces the formation of a low molecular weight isoform of striatal enriched tyrosine phosphatase (STEP). 10537057 1999
CUI: C0027092
Disease: Myopia
Myopia
0.100 GeneticVariation disease GWASCAT Detection and interpretation of shared genetic influences on 42 human traits. 27182965 2016
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.050 Biomarker group BEFREE Development and validation of simple step protein precipitation UHPLC-MS/MS methods for quantitation of temozolomide in cancer patient plasma samples. 30243056 2019
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.050 Biomarker group BEFREE In the next step, targeting ligand was conjugated on the minicell surface for the active targeting of cancer cell surface receptors. 31098999 2019
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.050 Biomarker group BEFREE Development and validation of simple step protein precipitation UHPLC-MS/MS methods for quantitation of temozolomide in cancer patient plasma samples. 30243056 2019
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.050 Biomarker group BEFREE In the next step, targeting ligand was conjugated on the minicell surface for the active targeting of cancer cell surface receptors. 31098999 2019
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.050 Biomarker group BEFREE Correction to: Oncology practitioners' perspectives and practice patterns of post-treatment cancer survivorship care in the Asia-Pacific region: results from the STEP study. 29495960 2018
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.050 Biomarker group BEFREE Correction to: Oncology practitioners' perspectives and practice patterns of post-treatment cancer survivorship care in the Asia-Pacific region: results from the STEP study. 29495960 2018
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.050 Biomarker group BEFREE Mapping unmet supportive care needs, quality-of-life perceptions and current symptoms in cancer survivors across the Asia-Pacific region: results from the International STEP Study. 28961835 2017
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.050 Biomarker group BEFREE Oncology practitioners' perspectives and practice patterns of post-treatment cancer survivorship care in the Asia-Pacific region: results from the STEP study. 29110686 2017
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.050 Biomarker group BEFREE Mapping unmet supportive care needs, quality-of-life perceptions and current symptoms in cancer survivors across the Asia-Pacific region: results from the International STEP Study. 28961835 2017
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.050 Biomarker group BEFREE Oncology practitioners' perspectives and practice patterns of post-treatment cancer survivorship care in the Asia-Pacific region: results from the STEP study. 29110686 2017
CUI: C0030193
Disease: Pain
Pain
0.030 AlteredExpression phenotype BEFREE Our results demonstrate that STEP61 is the molecular brake that is lost following KCC2-dependent disinhibition and that the decrease in STEP61 activity drives the potentiation of excitatory GluN2B NMDAR responses in rodent and human models of pathological pain. 31135041 2019
CUI: C0233794
Disease: Memory impairment
Memory impairment
0.030 Biomarker phenotype BEFREE In summary, our results support the key role of STEP in sepsis-induced memory impairment in a mouse model of SAE, whereas inhibition of STEP may provide a novel therapeutic approach for this disorder and possible other neurodegenerative diseases. 31691882 2019
CUI: C0020179
Disease: Huntington Disease
Huntington Disease
0.030 Biomarker disease BEFREE In conclusion, our results show that deletion of STEP has a beneficial effect on motor coordination and cognition in a mouse model of HD suggesting that STEP inhibition could be a good therapeutic strategy in HD patients. 30176350 2018
CUI: C0030193
Disease: Pain
Pain
0.030 Biomarker phenotype BEFREE Project STEP: Implementing the Veterans Health Administration's Stepped Care Model of Pain Management. 30203015 2018